Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04319783
Title Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)
Acronym DECREASE
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Trans Tasman Radiation Oncology Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.